Limiting AAA With Metformin (LIMIT) Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Abdominal Aortic Aneurysm
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Prospective, randomized, controlled trial comparing the ability of metformin to prevent AAA disease progression vs. placebo.Masking: Triple (Participant, Care Provider, Investigator)Masking Description: randomized (which means assigned by chance, like flipping a coin) into one of two groups. You will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 55 years and 90 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04500756
- Collaborators
- Kaiser Permanente
- VA Palo Alto Health Care System
- National Heart, Lung, and Blood Institute (NHLBI)
- Investigators
- Principal Investigator: Ronald Dalman, MD Stanford University
Get Well Soon